Incruse Ellipta 62.5 ug/1 (Umeclidinium AEROSOL, POWDER) 62.5 ug/1

Incruse Ellipta 62.5 ug/1 is a powder aerosol inhaler containing umeclidinium, used for managing chronic obstructive pulmonary disease (COPD). This maintenance medication helps improve breathing by relaxing airway muscles.

Strength

62.5 ug/1

Pack Size

1 TRAY in 1 CARTON (0173-0873-06) / 1 INHALER in 1 TRAY / 7 AEROSOL, POWDER in 1 INHALER

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Incruse Ellipta 62.5 ug/1 is primarily used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by relaxing the muscles around the airways, making it easier to breathe. This medication is not intended for immediate relief of sudden breathing problems but is designed for regular use to manage symptoms over time.

Side Effects

Common effects of Incruse Ellipta 62.5 ug/1 may include dry mouth, throat irritation, and cough. Some users might experience headaches or dizziness. These effects are generally mild and temporary, but if they persist or worsen, it is advisable to consult a healthcare professional.

Precautions & Warnings

Incruse Ellipta 62.5 ug/1 should be used as directed by a healthcare provider. It is important to follow the prescribed dosage and administration instructions. Patients with a history of severe hypersensitivity to umeclidinium or similar medications should avoid using this inhaler. Always store the inhaler in a clean, dry place and keep it out of reach of children.

Avoid Interactions

Incruse Ellipta 62.5 ug/1 may interact with other medications, including beta-agonists, anticholinergics, and certain antibiotics. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be moderated while using this medication, as it may exacerbate some side effects.

Frequently Asked Questions

Incruse Ellipta 62.5 ug/1 is used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD).

Incruse Ellipta 62.5 ug/1 should be used as directed by your healthcare provider. Follow the instructions provided with the inhaler for proper administration.

Common side effects may include dry mouth, throat irritation, cough, headaches, and dizziness.

No, Incruse Ellipta 62.5 ug/1 is not intended for immediate relief of sudden breathing problems. It is designed for regular use to manage COPD symptoms over time.

Store Incruse Ellipta 62.5 ug/1 in a clean, dry place and keep it out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.